Get the Stockscreener App
71.91
0.81%
0.58
After Hours:
71.91
Bright Minds Biosciences Inc stock is traded at $71.91, with a volume of 194.63K.
It is up +0.81% in the last 24 hours and up +9.30% over the past month.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$71.33
Open:
$70.92
24h Volume:
194.63K
Relative Volume:
0.63
Market Cap:
$705.59M
Revenue:
-
Net Income/Loss:
$-19.80M
P/E Ratio:
-29.44
EPS:
-2.4426
Net Cash Flow:
$-14.56M
1W Performance:
-3.62%
1M Performance:
+9.30%
6M Performance:
-15.40%
1Y Performance:
+102.82%
1-Day Range:
$70.16
$73.99
1-Week Range:
$70.16
$78.46
52-Week Range:
$31.80
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
71.91 | 699.89M | 0 | -19.80M | -14.56M | -2.4426 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Sep-08-25 | Initiated | BTIG Research | Buy |
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Bright Minds Biosciences Inc (DRUG) Cash Flow - TradingKey
40,000 Shares in Bright Minds Biosciences Inc. $DRUG Acquired by Orbimed Advisors LLC - MarketBeat
Bright Minds Biosciences Inc (DRUG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bright Minds Biosciences Inc (DRUG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bright Minds Biosciences Inc (DRUG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bright Minds Biosciences Inc (DRUG) Institutional Confidence - TradingKey
DRUG|Bright Minds Biosciences Inc|Price:71.330|Chg%:+0.040 - TradingKey
Bright Minds Biosciences Inc (DRUG) Balance Sheet - TradingKey
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High? - Yahoo Finance
Wall Street Analysts See a 27.16% Upside in Unity Software (U): Can the Stock Really Move This High? - Zacks Investment Research
Walleye Capital LLC Has $3.92 Million Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Upgraded at Zacks Research - MarketBeat
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy - Yahoo Finance
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 5%Should You Buy? - MarketBeat
Eli Lilly deal to buy AtaiBeckley (psychedelic) - KuCoin
Wall Street Analysts See a 27.35% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High? - Yahoo Finance
Bright Minds Biosciences (DRUG) Climbs 2.55% as Bullish Momentum Builds Near Key ResistanceConversion Trade - dars.gov.et
Draig bags another $65M to speed testing of brain drugs - Yahoo Finance
Understanding Momentum Shifts in (DRUG) - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 7.7%What's Next? - MarketBeat
Bright Minds Biosciences Inc Company Profile & Introduction - Moomoo
Epilepsy Pipeline Expands as 75+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com
Form 13D/A BRIGHT MINDS BIOSCIENCES INC. For: 2 July By Investing.com - Investing.com Canada
Ian McDonald reports 13.6% Bright Minds (DRUG) ownership stake - Stock Titan
Best TSX Healthcare Stocks to Watch for July 2026 - Kalkine Media
Avoiding Lag: Real-Time Signals in (DRUG) Movement - Stock Traders Daily
Canadian Securities Exchange Reports January 2026 Performance Figures - The Canadian Securities Exchange (CSE)
Bright Minds Biosciences (DRUG) Surges 3.51%, Testing Resistance at $75.19Equity Put Call - dars.gov.et
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
BrightSpring Health Services, Inc. (BTSG) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Bright Minds Biosciences Inc (DRUG) Stock Forum and Discussion - Moomoo
Bright Minds Biosciences (DRUG) Surges 3.38% as Shares Approach Resistance at $69.08On Balance Volume - dars.gov.et
DRUG Forecast — Price Target — Prediction for 2027 - TradingView
Bright Minds Biosciences Inc. Actuals & Estimates (CSE:DRUG) - TradingView
Bright Minds Biosciences Inc. (DRUG) Shows Modest Uptick, Testing Key ResistanceGap Fill Strategy - dars.gov.et
$ENA Forecast — Price Prediction for 2026. Should I Buy $ENA? - Intellectia AI
Bright Minds Biosciences (DRUG) Edges Lower Near Resistance Amid Quiet TradingHull Moving Average - dars.gov.et
DRUG Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Income Statement - Intellectia AI
DRUG Technical Analysis & Stock Price Forecast - Intellectia AI
Discipline and Rules-Based Execution in DRUG Response - Stock Traders Daily
Bright Minds Biosciences (DRUG) Advances 1.92% as Stock Tests Key ResistanceHigh Volume Node - dars.gov.et
Bright Minds Biosciences Inc (DRUG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bright Minds Biosciences Inc (DRUG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bright Minds Biosciences Inc - TradingKey
Bright Minds Biosciences Inc (DRUG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bright Minds Biosciences (DRUG) Slips Slightly, Consolidating Near Key Support LevelsMonthly Profile - dars.gov.et
Bright Minds Biosciences Inc (DRUG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bright Minds Biosciences (DRUG) Slides 1% as Buyers and Sellers Battle Near Critical LevelsBull Flag - newsline.com
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):